CA2515289A1 - Sels de faible basicite - Google Patents

Sels de faible basicite Download PDF

Info

Publication number
CA2515289A1
CA2515289A1 CA002515289A CA2515289A CA2515289A1 CA 2515289 A1 CA2515289 A1 CA 2515289A1 CA 002515289 A CA002515289 A CA 002515289A CA 2515289 A CA2515289 A CA 2515289A CA 2515289 A1 CA2515289 A1 CA 2515289A1
Authority
CA
Canada
Prior art keywords
salt
pharmaceutical composition
carbon atoms
less
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002515289A
Other languages
English (en)
Inventor
Samuel H. Yalkowsky
Tapan Sanghvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona Board of Regents of University of Arizona
Original Assignee
Arizona Board Of Regents On Behalf Of The University Of Arizona
Samuel H. Yalkowsky
Tapan Sanghvi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/402,347 external-priority patent/US7022712B2/en
Application filed by Arizona Board Of Regents On Behalf Of The University Of Arizona, Samuel H. Yalkowsky, Tapan Sanghvi filed Critical Arizona Board Of Regents On Behalf Of The University Of Arizona
Publication of CA2515289A1 publication Critical patent/CA2515289A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002515289A 2003-03-12 2004-03-12 Sels de faible basicite Abandoned CA2515289A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45403503P 2003-03-12 2003-03-12
US60/454,035 2003-03-12
US45451403P 2003-03-13 2003-03-13
US60/454,514 2003-03-13
US10/402,347 US7022712B2 (en) 2002-03-26 2003-03-26 Solubilization of weak bases
US10/402,347 2003-03-26
PCT/US2004/007786 WO2004081006A1 (fr) 2003-03-12 2004-03-12 Sels de faible basicite

Publications (1)

Publication Number Publication Date
CA2515289A1 true CA2515289A1 (fr) 2004-09-23

Family

ID=32995897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002515289A Abandoned CA2515289A1 (fr) 2003-03-12 2004-03-12 Sels de faible basicite

Country Status (6)

Country Link
EP (1) EP1606290A1 (fr)
JP (1) JP2006519852A (fr)
AU (1) AU2004220053A1 (fr)
CA (1) CA2515289A1 (fr)
MX (1) MXPA05009564A (fr)
WO (1) WO2004081006A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2367829B1 (fr) * 2008-11-19 2013-01-02 Cephalon, Inc. Nouvelles formes d'un composé indazolo [5,4-a] pyrrolo [3,4-c] carbazole
CA2745037C (fr) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Formes salines de 1-[(4-methyl-quinazoline-2-yl)methyl]-3-methyl-7-(2-butyne-1-yl)-8(3-(r)-amino-piperidine-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2731947B1 (fr) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement de la diabète type i et type ii
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (fr) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
EP3110449B1 (fr) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Utilisation médicale d'un inhibiteur de dpp-4
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195180A (en) * 1967-05-05 1970-06-17 Du Pont Use of Alkyl 2-Benzimidazole-Carbamate Salts a Fungicides
CA962588A (en) * 1972-05-17 1975-02-11 Her Majesty In Right Of Canada As Represented By The Minister Of The Env Ironment, And Canadian Patents And Development Limited Method, apparatus, and fungicides for the treatment of trees subject to dutch elm disease and other fungus diseases
JPS5459338A (en) * 1977-10-20 1979-05-12 Takeda Chem Ind Ltd Remedy for dermatomycosis
HU199431B (en) * 1985-02-04 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing carbendazim salts, and fungicide comprising such carbendazim salt as active ingredient
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer

Also Published As

Publication number Publication date
MXPA05009564A (es) 2005-11-17
AU2004220053A1 (en) 2004-09-23
WO2004081006A1 (fr) 2004-09-23
EP1606290A1 (fr) 2005-12-21
JP2006519852A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
CA2515289A1 (fr) Sels de faible basicite
ES2946489T3 (es) Formas sólidas y formulaciones de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida
ES2732360T3 (es) Forma cristalina del 4-[5-(piridin-4-il)-1H-1,2,4-triazol-3-il]piridin-2-carbonitrilo
JP5433413B2 (ja) 短時間作用型ベンゾジアゼピンの塩およびそれらの多形形態
JP7134294B2 (ja) 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用
CA2943998C (fr) Sel de 1-(2-desoxy-2-fluoro-4-thio-.beta.-d-arabinofuranosyl)cytosine
JP6370377B2 (ja) 非晶質形態のダサチニブの塩
JP2018531280A6 (ja) 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
BR112016002770B1 (pt) Sal de hemissulfato de ácido 5,10-metileno-(6r)-tetra-hidrofólico, sua composição farmacêutica e seu uso
HU231013B1 (hu) Dasatinib sók
Caira et al. Polymorphism and pseudopolymorphism of the antibacterial nitrofurantoin
PT2448945E (pt) Formas cristalinas de sais de prasugrel
US20070043070A1 (en) Weak base salts
ES2716633T3 (es) Formas cristalinas de fosfato de cabozantinib e hidrocloruro de cabozantinib
US10344041B2 (en) Polymorphic forms and co-crystals of a c-Met inhibitor
US8530501B2 (en) Salts and crystalline forms of a factor Xa inhibitor
EP4169914A1 (fr) Sel de composé et composition pharmaceutique le contenant
BR102021009918A2 (pt) Dispersão sólida do antibiótico rifampicina
US5401842A (en) Injectable compositions of a cephalosporin dihydrate salt
EP3455229B1 (fr) Nouvelles formes cristallines

Legal Events

Date Code Title Description
FZDE Discontinued